Q-omics provides the consensus-scored NDUFS3 profile across patient tissues and cancer cell-line models. NDUFS3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFS3 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, NDUFS3 protein abundance shows 26,569 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, LIHC, and GBM as cancer lineages where NDUFS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFS3 survival associations across molecular data types. NDUFS3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFS3 RNA expression–survival associations across cancer types. High NDUFS3 expression shows unfavorable associations in UVM, ACC, KICH and LIHC, but favorable associations in KIRP and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFS3 RNA expression.
This table summarizes NDUFS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFS3 shows lower tumor expression in KIRP and KIRC and higher tumor expression in LIHC, LUSC, BRCA and UCEC. The LIHC box plot shows higher NDUFS3 RNA expression in tumor versus normal tissue (log2 FC = +0.939, t-test p < 0.001).
This table shows molecular features associated with NDUFS3 in patient tissues and cancer cell lines. In patient samples, NDUFS3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
